Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of “Buy” by Brokerages
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned an average rating of “Buy” from the eleven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $9.29.
Several research analysts have recently issued reports on the company. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Leerink Swann upgraded Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $6.00 in a research report on Thursday, May 18th. TheStreet cut Achillion Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Wednesday, March 22nd. Finally, Robert W. Baird lifted their price target on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, April 24th.
A number of hedge funds have recently modified their holdings of ACHN. State Street Corp raised its stake in shares of Achillion Pharmaceuticals by 40.1% in the fourth quarter. State Street Corp now owns 5,121,160 shares of the biopharmaceutical company’s stock valued at $21,153,000 after buying an additional 1,465,723 shares during the last quarter. Norges Bank purchased a new stake in shares of Achillion Pharmaceuticals during the fourth quarter worth about $4,623,000. Vanguard Group Inc. raised its stake in shares of Achillion Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock worth $40,357,000 after buying an additional 646,415 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter worth about $2,526,000. Finally, HealthInvest Partners AB purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter worth about $2,096,000. 71.27% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/07/17/achillion-pharmaceuticals-inc-achn-given-consensus-recommendation-of-buy-by-brokerages.html.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) opened at 4.48 on Monday. The stock’s 50 day moving average is $4.29 and its 200 day moving average is $4.09. The stock’s market cap is $612.52 million. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. During the same period in the previous year, the firm earned ($0.13) earnings per share. On average, equities analysts predict that Achillion Pharmaceuticals will post ($0.64) EPS for the current fiscal year.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.